🚀 VC round data is live in beta, check it out!
Qingdao Baheal Medical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Qingdao Baheal Medical and similar public comparables like Jafron Biomedical, Flyco, Coty, Axogen and more.
Qingdao Baheal Medical Overview
About Qingdao Baheal Medical
Qingdao Baheal Medical Inc is engaged in providing comprehensive marketing services for pharmaceutical product manufacturers.
Founded
2005
HQ
Employees
N/A
Website
Financials (LTM)
EV
$2B
Qingdao Baheal Medical Financials
Qingdao Baheal Medical reported last 12-month revenue of $1B and EBITDA of $158M.
In the same LTM period, Qingdao Baheal Medical generated $430M in gross profit, $158M in EBITDA, and $97M in net income.
Revenue (LTM)
Qingdao Baheal Medical P&L
In the most recent fiscal year, Qingdao Baheal Medical reported revenue of $1B and EBITDA of $166M.
Qingdao Baheal Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $430M | XXX | $421M | XXX | XXX | XXX |
| Gross Margin | 36% | XXX | 36% | XXX | XXX | XXX |
| EBITDA | $158M | XXX | $166M | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 14% | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $97M | XXX | $101M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | — | — | $109M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Qingdao Baheal Medical Stock Performance
Qingdao Baheal Medical has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Qingdao Baheal Medical's stock price is $3.89.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 1.1% | XXX | XXX | XXX | $0.19 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialQingdao Baheal Medical Valuation Multiples
Qingdao Baheal Medical trades at 1.8x EV/Revenue multiple, and 14.0x EV/EBITDA.
EV / Revenue (LTM)
Qingdao Baheal Medical Financial Valuation Multiples
As of April 18, 2026, Qingdao Baheal Medical has market cap of $2B and EV of $2B.
Equity research analysts estimate Qingdao Baheal Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Qingdao Baheal Medical has a P/E ratio of 21.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 14.0x | XXX | 13.3x | XXX | XXX | XXX |
| EV/EBIT | 16.3x | XXX | 14.9x | XXX | XXX | XXX |
| EV/Gross Profit | 5.1x | XXX | 5.2x | XXX | XXX | XXX |
| P/E | 21.2x | XXX | 20.2x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 29.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Qingdao Baheal Medical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Qingdao Baheal Medical Margins & Growth Rates
Qingdao Baheal Medical's revenue in the last 12 month grew by 9%.
Qingdao Baheal Medical's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Qingdao Baheal Medical's rule of X is 39% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Qingdao Baheal Medical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | (2%) | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | (12%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 39% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 19% | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 23% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Qingdao Baheal Medical Public Comps
See public comps and valuation multiples for other Health & Beauty and Healthcare Software comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Qingdao Baheal Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Jafron Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| Flyco | XXX | XXX | XXX | XXX | XXX | XXX |
| Coty | XXX | XXX | XXX | XXX | XXX | XXX |
| Axogen | XXX | XXX | XXX | XXX | XXX | XXX |
| Establishment Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Qingdao Baheal Medical M&A Activity
Qingdao Baheal Medical acquired XXX companies to date.
Last acquisition by Qingdao Baheal Medical was on XXXXXXXX, XXXXX. Qingdao Baheal Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Qingdao Baheal Medical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialQingdao Baheal Medical Investment Activity
Qingdao Baheal Medical invested in XXX companies to date.
Qingdao Baheal Medical made its latest investment on XXXXXXXX, XXXXX. Qingdao Baheal Medical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Qingdao Baheal Medical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Qingdao Baheal Medical
| When was Qingdao Baheal Medical founded? | Qingdao Baheal Medical was founded in 2005. |
| Where is Qingdao Baheal Medical headquartered? | Qingdao Baheal Medical is headquartered in China. |
| Is Qingdao Baheal Medical publicly listed? | Yes, Qingdao Baheal Medical is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Qingdao Baheal Medical? | Qingdao Baheal Medical trades under 301015 ticker. |
| When did Qingdao Baheal Medical go public? | Qingdao Baheal Medical went public in 2021. |
| Who are competitors of Qingdao Baheal Medical? | Qingdao Baheal Medical main competitors are Jafron Biomedical, Flyco, Coty, Axogen. |
| What is the current market cap of Qingdao Baheal Medical? | Qingdao Baheal Medical's current market cap is $2B. |
| What is the current revenue of Qingdao Baheal Medical? | Qingdao Baheal Medical's last 12 months revenue is $1B. |
| What is the current revenue growth of Qingdao Baheal Medical? | Qingdao Baheal Medical revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Qingdao Baheal Medical? | Current revenue multiple of Qingdao Baheal Medical is 1.8x. |
| Is Qingdao Baheal Medical profitable? | Yes, Qingdao Baheal Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Qingdao Baheal Medical? | Qingdao Baheal Medical's last 12 months EBITDA is $158M. |
| What is Qingdao Baheal Medical's EBITDA margin? | Qingdao Baheal Medical's last 12 months EBITDA margin is 13%. |
| What is the current EV/EBITDA multiple of Qingdao Baheal Medical? | Current EBITDA multiple of Qingdao Baheal Medical is 14.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.